Trade Names:Colace- Capsules 50 mg- Capsules 100 mg- Liquid 150 mg/15 mL- Syrup 60 mg/15 mL
Trade Names:Diocto- Liquid 150 mg/15 mL- Syrup 60 mg/15 mL
Trade Names:Docu- Liquid 150 mg/15 mL- Syrup 20mg/5 mL
Trade Names:D.O.S.- Capsules, soft-gel 100 mg- Capsules, soft-gel 250 mg
Trade Names:D-S-S- Capsules 100 mg
Trade Names:ex-lax Stool Softener- Tablets 100 mg
Trade Names:Genasoft- Capsules, soft-gel 100 mg
Trade Names:Non-Habit Forming Stool Softener- Capsules 100 mg
Trade Names:Phillips' Liqui-Gels- Capsules, soft-gel 100 mg
Trade Names:Silace- Syrup 60 mg/15 mL
Trade Names:Stool Softener- Capsules 100 mg- Capsules 250 mgSelax (Canada)Soflax (Canada)ratio-Docusate Sodium (Canada)Docusate Calcium (Dioctyl Calcium Sulfosuccinate)
Trade Names:DC Softgels- Capsules 240 mg
Trade Names:Stool Softener- Capsules 240 mg
Trade Names:Stool Softener DC- Capsules 240 mg
Trade Names:Surfak Liquigels- Capsules 240 mgApo-Docusate Sodium (Canada)ratio-Docusate Calcium (Canada)
Facilitates stool softening by detergent activity.
12 to 72 h.
Short-term treatment of constipation; prophylaxis in patients who should not strain during defecation (eg, after anorectal surgery, MI); to evacuate the colon for rectal and bowel examinations; prevention of dry, hard stools.
Nausea, vomiting or other symptoms of appendicitis; acute surgical abdomen; fecal impaction; intestinal obstruction; undiagnosed abdominal pain; coadministration with mineral oil.
PO 50 to 500 mg.Children 6 to 12 yr of age
PO 40 to 120 mg.Children 3 to 6 yr of age
PO 20 to 60 mg.Children younger than 3 yr of age
PO 10 to 40 mg.Docusate CalciumAdults
PO 240 mg.Children 6 yr of age and older and Adults With Minimal Needs
PO 50 to 150 mg.
Store capsules at room temperature. Protect liquid preparations from light.
Docusate may increase absorption of mineral oil from GI tract, leading to toxicity.
None well documented.
Excessive bowel activity (griping, diarrhea, nausea, vomiting); perianal irritation; bloating; flatulence; abdominal cramping.
Evaluate and document patient's response to stool softener, noting any adverse reactions such as nausea, vomiting, abdominal cramping, or diarrhea.
Category C .
Long-term use may lead to laxative dependence, fluid and electrolyte imbalances, steatorrhea, osteomalacia, and vitamin and mineral deficiencies.
Excessive laxative use may lead to significant fluid and electrolyte imbalance.
May indicate serious condition that may require further medical attention.
Do not use other laxatives, especially during the initial phase of therapy for portal-systemic encephalopathy; the resulting loose stools may falsely suggest adequate lactulose dosage.
Copyright © 2009 Wolters Kluwer Health.